Two Sigma Investments
RNTX

Two Sigma Investments’s Rein Therapeutics RNTX Stock Holding History

Two Sigma Investments’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,709
Closed -$48.4K – 5007
2025
Q4 		$48.4K Buy
+41,709
New +$57.5K ﹤0.01% 3941
2021
Q2 		– Sell
-2,255
Closed -$64K – 4665
2021
Q1 		$64K Buy
+2,255
New +$77.3K ﹤0.01% 3732

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Two Sigma Investments's RNTX Position: Q1 2026 in Review

Two Sigma Investments sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 41,709 shares — an estimated $48.4K sold.

Two Sigma Investments first reported a position in RNTX in Q1 2021 and held it in 2 quarters. The position peaked at $64K in Q1 2021. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Two Sigma Investments reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Investments sold 41,709 Rein Therapeutics shares in Q1 2026, an estimated $48.4K.
  • Two Sigma Investments first reported a position in Rein Therapeutics in Q1 2021 and held it in 2 quarters.
  • Two Sigma Investments's Rein Therapeutics position peaked at $64K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.